{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:45:18Z","timestamp":1792107918118,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00467-026-07397-1","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:40:00Z","timestamp":1781253600000},"page":"4423-4432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4798-3509","authenticated-orcid":false,"given":"Taishi","family":"Nada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-6961","authenticated-orcid":false,"given":"Koichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3436-0392","authenticated-orcid":false,"given":"Kentaro","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kamigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7057-2475","authenticated-orcid":false,"given":"Toru","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6388-1800","authenticated-orcid":false,"given":"Aya","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-8987","authenticated-orcid":false,"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"7397_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002290.pub5","volume":"4","author":"NG Larkins","year":"2020","unstructured":"Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM (2020) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 4:CD002290. https:\/\/doi.org\/10.1002\/14651858.CD002290.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"7397_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"7397_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D, International Pediatric Nephrology Association (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3","journal-title":"Pediatr Nephrol"},{"key":"7397_CR4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","volume":"23","author":"EM Dorresteijn","year":"2008","unstructured":"Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate Mofetil versus Cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23:2013\u20132020. https:\/\/doi.org\/10.1007\/s00467-008-0899-6","journal-title":"Pediatr Nephrol"},{"key":"7397_CR5","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1681\/ASN.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann J, Weber L, Pape L, T\u00f6nshoff B, Hoyer P, Querfeld U, Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie (2013) Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24:1689\u20131697. https:\/\/doi.org\/10.1681\/ASN.2012121200","journal-title":"J Am Soc Nephrol"},{"key":"7397_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","volume":"21","author":"K Iijima","year":"2017","unstructured":"Iijima K, Sako M, Nozu K (2017) Rituximab for nephrotic syndrome in children. Clin Exp Nephrol 21:193\u2013202. https:\/\/doi.org\/10.1007\/s10157-016-1313-5","journal-title":"Clin Exp Nephrol"},{"key":"7397_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281. https:\/\/doi.org\/10.1016\/S0140-6736(14)60541-9","journal-title":"Lancet"},{"key":"7397_CR8","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl\u2019Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259\u20132266. https:\/\/doi.org\/10.1681\/ASN.2014080799","journal-title":"J Am Soc Nephrol"},{"key":"7397_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha IS, Cheong HI, Kim SY, Lee SJ, Kang HG (2018) Efficacy and safety of Rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine (Baltimore) 97:e13157. https:\/\/doi.org\/10.1097\/MD.0000000000013157","journal-title":"Medicine (Baltimore)"},{"key":"7397_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of Rituximab vs Tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172:757\u2013764. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.1323","journal-title":"JAMA Pediatr"},{"key":"7397_CR11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00467-020-04540-4","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Lugani F, Pisani I, Bodria M, Piaggio G, Bartolomeo D, Prunotto M, Ghiggeri GM (2020) Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol 35:1437\u20131444. https:\/\/doi.org\/10.1007\/s00467-020-04540-4","journal-title":"Pediatr Nephrol"},{"key":"7397_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5114\/aoms\/145587","volume":"18","author":"L Wang","year":"2022","unstructured":"Wang L, Zhu J, Xia M, Hua R, Deng F (2022) Comparison of Rituximab, Cyclophosphamide, and Tacrolimus as first steroid-sparing agents for complicated relapsing\/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life. Arch Med Sci 18:275\u2013278. https:\/\/doi.org\/10.5114\/aoms\/145587","journal-title":"Arch Med Sci"},{"key":"7397_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2021050643","volume":"33","author":"K Iijima","year":"2022","unstructured":"Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K, Japanese Study Group of Kidney Disease in Children (2022) Mycophenolate mofetil after Rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol 33:401\u2013419. https:\/\/doi.org\/10.1681\/ASN.2021050643","journal-title":"J Am Soc Nephrol"},{"key":"7397_CR14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K (2011) Maintenance therapy with Mycophenolate mofetil after Rituximab in pediatric patients with steroid-dependent Nephrotic syndrome. Pediatr Nephrol 26:1823\u20131828. https:\/\/doi.org\/10.1007\/s00467-011-1886-x","journal-title":"Pediatr Nephrol"},{"key":"7397_CR15","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s10157-025-02744-2","volume":"29","author":"T Nada","year":"2025","unstructured":"Nada T, Kamei K, Nishi K, Uchimura T, Inaba A, Ogura M, Hamada R, Hataya H, Ito S (2025) Long-term outcome of Mycophenolate mofetil after a single dose of Rituximab in childhood-onset refractory Idiopathic nephrotic syndrome. Clin Exp Nephrol 29:1829\u20131839. https:\/\/doi.org\/10.1007\/s10157-025-02744-2","journal-title":"Clin Exp Nephrol"},{"key":"7397_CR16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00467-023-06270-9","volume":"39","author":"Y Sobue","year":"2024","unstructured":"Sobue Y, Nishi K, Kamei K, Inoki Y, Osaka K, Kaneda T, Akiyama M, Sato M, Ogura M, Ishikura K, Ishiguro A, Ito S (2024) Feasibility of discontinuing immunosuppression in children with Idiopathic nephrotic syndrome. Pediatr Nephrol 39:1825\u20131835. https:\/\/doi.org\/10.1007\/s00467-023-06270-9","journal-title":"Pediatr Nephrol"},{"key":"7397_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/ajkd.2003.50116","volume":"41","author":"F Fakhouri","year":"2003","unstructured":"Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Gr\u00fcnfeld JP, Niaudet P (2003) Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41:550\u2013557. https:\/\/doi.org\/10.1053\/ajkd.2003.50116","journal-title":"Am J Kidney Dis"},{"key":"7397_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5414\/CN108044","volume":"81","author":"P Skrzypczyk","year":"2014","unstructured":"Skrzypczyk P, Panczyk-Tomaszewska M, Roszkowska-Blaim M, Wawer Z, Bienias B, Zajgzkowska M, Kilis-Pstrusinska K, Jakubowska A, Szczepaniak M, Pawlak-Bratkowska M, Tkaczyk M (2014) Long-term outcomes in Idiopathic nephrotic syndrome: from childhood to adulthood. Clin Nephrol 81:166\u2013173. https:\/\/doi.org\/10.5414\/CN108044","journal-title":"Clin Nephrol"},{"key":"7397_CR19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","volume":"32","author":"K Kamei","year":"2017","unstructured":"Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of Rituximab. Pediatr Nephrol 32:2071\u20132078. https:\/\/doi.org\/10.1007\/s00467-017-3718-0","journal-title":"Pediatr Nephrol"},{"key":"7397_CR20","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ekir.2024.02.1395","volume":"9","author":"J Liu","year":"2024","unstructured":"Liu J, Deng F, Wang X, Liu C, Sun S, Zhang R, Zhang A, Jiang X, Yan W, Dou Y, Zhang Y, Xie L, Qian B, Shen Q, Xu H (2024) Early Rituximab as an add-on therapy in children with the initial episode of Nephrotic syndrome. Kidney Int Rep 9:1220\u20131227. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.1395","journal-title":"Kidney Int Rep"},{"key":"7397_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19214-0","volume":"15","author":"K Iijima","year":"2025","unstructured":"Iijima K, Sako M, Horinouchi T, Sakai T, Yamamura T, Hamada R, Ohtsuka Y, Tanaka S, Kamei K, Tanaka R, Kano Y, Kubota T, Shima Y, Morohashi T, Inaba A, Fujinaga S, Oka M, Kaito H, Konishi A, Nagano C, Nakanishi K, Ishikura K, Ito S, Nakamura H, Ghiggeri GM, Mori R, Omori T, Nozu K, Japanese Study Group of Kidney Disease in Children JSKDC10 Study (2025) Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study. Sci Rep 15:34306. https:\/\/doi.org\/10.1038\/s41598-025-19214-0","journal-title":"Sci Rep"},{"key":"7397_CR22","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rav\u00e0 L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after Rituximab treatment in Idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822. https:\/\/doi.org\/10.1681\/ASN.2015050523","journal-title":"J Am Soc Nephrol"},{"key":"7397_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1463429","volume":"15","author":"A Krawczyk","year":"2025","unstructured":"Krawczyk A, Krav\u010denia B, Ma\u015blanka T (2025) Mycophenolate mofetil: an update on its mechanism of action and effect on lymphoid tissue. Front Immunol 15:1463429. https:\/\/doi.org\/10.3389\/fimmu.2024.1463429","journal-title":"Front Immunol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07397-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07397-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07397-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:54:20Z","timestamp":1792104860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07397-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["7397"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07397-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the National Center for Child Health and Development (approval number, 2021-219).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for participating in this study was not required in accordance with the principles of the Declaration of Helsinki and Ethical Guidelines for Medical and Biological Research Involving Human Subjects by the Ministry of Health, Labour and Welfare, Japan.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for publication was waived in accordance with the guidelines.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koichi Kamei has received research funding from the Public Foundation of Vaccination Research Center and the Taiju Life Social Welfare Foundation; donations from Chugai Pharmaceutical Co. Ltd., Teijin Pharma Ltd., Kyowa Kirin Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; and lecture fees from Terumo Co., Ltd., Baxter Ltd., and Zenyaku Kogyo Co., Ltd. The other authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}